Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 2/20 | 0.50 |
| ▸ | PTPRC | P08575 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31272464 | 1.00 | S100A4 (0.50) | S100A4PTPRCMAPTRECQLKMT2A | |
| SCHEMBL3039191 | 0.73 | TDP1 (0.67) | S100A4PTPRCMAPTRECQLKMT2A | |
| SCHEMBL33377367 | 0.69 | CA1 (0.36) | CA1CA2CA7CA9 | |
| SCHEMBL244916 | 0.69 | S100A4 (0.61) | S100A4PTPRCMAPTRECQLKMT2A | |
| SCHEMBL8979627 | 0.69 | S100A4 (0.61) | S100A4PTPRCMAPTRECQLKMT2A | |
| SCHEMBL4752952 | 0.69 | S100A4 (0.52) | S100A4PTPRCMAPTRECQLKMT2A | |
| SCHEMBL28734159 | 0.69 | TDP1 (0.46) | S100A4PTPRCMAPTKMT2ATDP1 | |
| SCHEMBL2927806 | 0.68 | S100A4 (0.55) | S100A4PTPRCMAPTRECQLKMT2A | |
| SCHEMBL2599501 | 0.67 | S100A4 (1.00) | S100A4PTPRCMAPTRECQLKMT2A | |
| SCHEMBL2347136 | 0.67 | S100A4 (0.84) | S100A4PTPRCMAPTRECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| EP-4163278-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (CN) | 2023-04-12 | — | — | EP | disclosed |
| EP-2486012-B1 | PROCESSES FOR THE PREPARATION OF 2-(1-PHENYLETHYL) ISOINDOLIN-1-ONE COMPOUNDS | CELGENE CORP (US) | 2013-12-11 | — | — | EP | disclosed |
| US-8415485-B2 | Processes for the preparation of 2-(1-phenylethyl)isoindolin-1-one compounds | CELGENE CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20110087033-A1 | Processes for the Preparation of 2-(1-Phenylethyl)isoindolin-1-one Compounds | AMGEN INC. | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087033-A1 | Processes for the Preparation of 2-(1-Phenylethyl)isoindolin-1-one Compounds | PNMT, CYP2E1, CYP1A1 | S100A4 3312/4885PTPRC 3287/4885MAPT 673/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | S100A4 3678/4885PTPRC 4319/4885MAPT 2789/4885 |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | AXL, FLT3, TYMP | S100A4 4140/4885PTPRC 998/4885MAPT 2663/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | S100A4 3678/4885PTPRC 4319/4885MAPT 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.